Michael Pitt a professor of pediatrics at the University of Minnesota School of Medicine outlined how the medical education system can adapt to the challenges of the future during a speech at the Manova Summit in Minneapolis.
An entrepreneur panel at the Manova Summit in Minneapolis, Minnesota delved into the subject of how mental health digital therapeutics augment – instead of interrupt – the work of clinicians and care professionals.
The Pediatric Device Innovation Consortium is looking to give unlikely but important pediatric medical device ideas an actual chance at production. Getting ideas from parents is key.
Minnesota startup Embomedics is developing resorbable transarterial chemoembolization microspheres (that’s a mouthful), and is in the midst of a $5 million equity raise to bring ’em to fruition, according to a regulatory filing. In essence, it has created biodegradable hollow beads that can deliver drugs to a localized tumor site, and additionally block off blood flow to the area […]
EmboMedics, a Maple Grove, Minn.-based medical device company, has raised $860,000 in equity, according to a regulatory filing made with the SEC. The Series A funding will go mainly toward research and development of its resorbable embolization material, Omid Souresrafil, EmboMedics CEO and co-founder, said. He said the money should take the company through the […]
Imagine being able to turn off the alarm clock, start the coffee pot or flip a light switch with a simple arm movement. That’s the vision Playtabase has for the new wearable it’s developed with people who have limited mobility in mind. Called Reemo, the device is a wrist-worn band that interprets movements into gestures […]
A specialty drug is a class of prescription medications used to treat complex, chronic or rare medical conditions. Although this classification was originally intended to define the treatment of rare, also termed “orphan” diseases, affecting fewer than 200,000 people in the US, more recently, specialty drugs have emerged as the cornerstone of treatment for chronic and complex diseases such as cancer, autoimmune conditions, diabetes, hepatitis C, and HIV/AIDS.
Minnesota entrepreneurs and their counterparts across the nation, listen up. Two new funds are expected to launch in July to help you survive the investment valley of death. University of Minnesota President Eric Kaler told an audience of healthcare entrepreneurs and investors Tuesday that the university will launch two funds next year, pending approval from […]
Under the leadership of Jay Schrankler, University of Minnesota’s Office for Technology Commercialization licensed 12 technologies in fiscal 2012 turning around the university’s tech transfer operation that many considered lackluster even a few years ago. Among the 12, there are six that play in the healthcare industry or have applications in it. Ariel Pharmaceuticals This […]
The University of Minnesota announced Wednesday that it has received a $1.08 million grant from the Minnesota Department of Employment and Economic Development that will be used to fund construction of a new Medical Devices Center. The Medical Devices Center is currently housed in 5,000 square feet of space in the Shepherd Labs building on the University’s […]
The University of Minnesota confirmed that vice president of research Tim Mulcahy will be departing in December after almost eight years on the job. In a phone interview, Mulcahy said that he plans to retire to spend more time with grandchildren, travel with his wife, pursue photography and do the things he has not had the time to do in the last 17 years.
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
The University of Minnesota announced Thursday that it has granted an exclusive license to a San Francisco pharmaceutical company that will commercialize a cyanide-poisoning antidote researchers have developed. Vytacera Pharma Inc. will develop and market Sulfanegen, a compound that can be administered by first responders to victims of smoke inhalation or a large-scale terrorist attack. Current […]
Medical device design usually involves the use of computer-aided design and computer-aided manufacturing, or CAD/CAM environments. The process is long and iterative. Now, two professors at the University of Minnesota have come up with a 3-D visualization device that aims to revolutionize how medical devices are designed and tested, thereby shortening R&D cycles and the […]
The old Medtronic Infuse controversy is being stirred up again. The Milwaukee Journal Sentinel today published a story on Thomas Zdeblick, the chairman of the Department of Orthopedics & Rehabilitation at the University of Wisconsin-Madison, who has received more than $25 million in royalties from Medtronic since 2003. The article calls to question Zdeblick’s position […]
Three diabetes-related research projects at Mayo Clinic and the University of Minnesota received more than $1.8 million through a state-funded research initiative for preventing, treating and curing diabetes. Decade of Discovery is an initiative of the Minnesota Partnership for Biotechnology and Medical Genomics, a collaboration between the university, the clinic and the state of Minnesota. […]
We often hear about medical device approvals, how they are performing in clinical trials, etc, etc. But where are these devices born? How does a medical device go from idea to approval? One answer: the Medical Devices Center at the University of Minnesota. In this interview, Dr. Art Erdman tells us how the unique Medical […]
